Stockreport

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF The company reported positive outcomes from the BROOKLYN, TANDEM, and BROADWAY trials, with up to 50% LDL-C reduction in combination with ezetimibe. EMA accepted Mark [Read more]